Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Molecular Analysis for Therapy Choice (MATCH)
Anatomic Site:
Any
Histology:
Advanced Malignant Neoplasm, Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Solid Neoplasm, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
Mutation:
EGFR, HER2, EGFR T790M, BRAF V600E/R/K/D, PIK3CA, PTEN, PTEN deletion, PTEN loss, HER2 amplification, BRAF fusion, BRAF non-V600, NF 1, GNAQ, GNA11, SMO, PTCH1, NF2 inactivating, cKIT exon 9, cKIT exon 11, cKIT exon 13, cKIT exon 14, FGFR pathway aberrations, DDR2 S768R, I638F, L239R, Akt, NRAS in codon 12, NRAS in codon 13, NRAS in codon 61, CCND1, 2, or 3 amplification with Rb by IHC, Loss of MLH1 or MSH2 by IHC.
Stage:
Advanced
Treatment Phase:  Patient must have histologically documented solid tumors or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy. Patients must have progressed following at least one line of standard systemic therapy; no standard treatment exists for their disease. Must have measurable disease
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Donald Gravenor, MD
Locations Where Open:
Locations Where Open: Memphis
Formal Study Name:  The National Myelodysplastic Syndromes (MDS) Study
Anatomic Site:
Blood and Marrow
Histology:
Myelodysplastic Syndromes (MDS)
Mutation:
Stage:
Any
Treatment Phase:  Patients suspected to have MDS and are undergoing diagnostic work-up with planned bone marrow assessments to confirm MDS or to evaluate disease status.
Trial Phase:
  
Trial Type:
  Observational
Principal Investigator:
  Salil Goorha, MD
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto, NEA
Formal Study Name:  A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Breast Cancer with Positive Sentinel Lymph Node(s)
Mutation:
Stage:
Stage II, Stage IIIA
Treatment Phase:  No previous neoadjuvant endocrine or radiation therapy. No SLN surgery.
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Lindi VanderWalde, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany
Formal Study Name:  Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle InvaSive and Locally Advanced Urothelial CaRcinoma (AMBASSADOR) Versus Observation
Anatomic Site:
Bladder, Renal Pelvis and Urothelial Carcinoma
Histology:
Any
Mutation:
N/A
Stage:
Localized, Locally Advanced, II or III
Treatment Phase:  Any
Trial Phase:
  III
Trial Type:
  Treatment and Observation
Principal Investigator:
  Dr. Shailesh Satpute
Locations Where Open:
Locations Where Open: Memphis
Formal Study Name:  Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Anatomic Site:
Stomach, Colon, Prostate, Pancreas, Liver, Bladder, Kidney
Histology:
Any
Mutation:
N/A
Stage:
N/A
Treatment Phase:  Patients must have known or suspected cancer diagnosis and have planned surgery
Trial Phase:
  N/A
Trial Type:
  Cancer Care Delivery Research
Principal Investigator:
  Dr. Stephen Behrman
Locations Where Open:
Locations Where Open: Women's
Formal Study Name:  Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Anatomic Site:
Breast
Histology:
Ductal Carcinoma In Situ
Mutation:
ER(+) and/or PR(+) by IHC (≥ 10% staining or Allred score ≥ 4) unless atypia
Stage:
verging on DCIS in which case biomarker criterion does not apply; HER2 0, 1+, or 2+ by IHC if HER2 testing is performed
Treatment Phase:  Diagnosis of unilateral, bilateral, unifocal, multifocal, or multicentric DCIS without invasive breast cancer (date of diagnosis defined as the date of the first pathology report that diagnosed the patient with DCIS) OR: atypia verging on DCIS OR: DCIS + LCIS (mix and/or separate locations in the same breast); A patient who has had a lumpectomy or partial mastectomy with margins positive for DCIS (i.e. <2mm/ink on tumor) as part of their treatment for a current DCIS diagnosis is also eligible (post-excision bilateral mammogram required at enrollment to establish a new baseline)
Trial Phase:
  
Trial Type:
  Treatment, Surveillance
Principal Investigator:
  Dr. Alyssa Throckmorton
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, NEA
Formal Study Name:  A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Anatomic Site:
Anal Cancer
Histology:
Anal Basaloid, Anal Canal Cloacogenic, Anal Margin Squamous Carcinoma, or other Anal Cancer
Mutation:
N/A
Stage:
IIB, IIIA, IIIB, or IIIC
Treatment Phase:  Any
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Donald Gravenor
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Anatomic Site:
Any malignancy
Histology:
Mutation:
Stage:
Any
Treatment Phase:  
Trial Phase:
  III
Trial Type:
  Cancer Control and Prevention
Principal Investigator:
  Alexander Quesenberry, PharmD
Locations Where Open:
Locations Where Open: Memphis
Formal Study Name:  Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
Anatomic Site:
Any
Histology:
Breast Cancer, Prostate Cancer, Colorectal Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma
Mutation:
Stage:
Treatment Phase:  
Trial Phase:
  
Trial Type:
  
Principal Investigator:
  Philip Lammers, MD
Study Link:  
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto
Formal Study Name:  Implementing a Virtual Tobacco Treatment in Community Oncology Practices: "Smoke Free Support Study 2.0"
Anatomic Site:
Any cancer diagnosis within the last four months
Histology:
Mutation:
Stage:
Any
Treatment Phase:  
Trial Phase:
  II
Trial Type:
  Cancer Care Delivery Research
Principal Investigator:
  Dr. Alyssa Throckmorton
Locations Where Open:
Locations Where Open: Memphis, Oxford
Formal Study Name:  Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Anatomic Site:
Any
Histology:
Mutation:
Stage:
Treatment Phase:  
Trial Phase:
  
Trial Type:
  Observational
Principal Investigator:
  Raymond Osarogiagbon, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Anatomic Site:
Breast
Histology:
HER2 Positive
Mutation:
N/A
Stage:
I, II, or III
Treatment Phase:  Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Women’s
Formal Study Name:  Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHARES)
Anatomic Site:
Breast
Histology:
Any
Mutation:
Any
Stage:
0-III
Treatment Phase:  Newly diagnosed
Trial Phase:
  N/A
Trial Type:
  Cancer Control Delivery Research
Principal Investigator:
  Dr. Alyssa Throckmorton
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Anatomic Site:
Breast
Histology:
Any
Mutation:
Hormone receptor -positive or hormone receptor- negative HER2-positive breast cancer are eligible
Stage:
II through IIIA
Treatment Phase:  Patient must have histologically confirmed HER2-positive primary invasive breast carcinoma
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Dr. Drew Dill
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto, Oxford
Formal Study Name:  Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Anatomic Site:
Breast
Histology:
Any
Mutation:
Any
Stage:
I, II, or III
Treatment Phase:  Patients must be women with a known stage I-III invasive breast cancer diagnosis. Registration must occur within 84 days from the date of diagnosis
Trial Phase:
  II
Trial Type:
  Cancer Control and Prevention; Supportive Care
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto, Oxford, Grenada, New Albany, GTR, NEA
Formal Study Name:  A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Anatomic Site:
Breast
Histology:
Invasive; Triple Negative
Mutation:
Estrogen receptor (ER)-, progesterone receptor (PR)- and HER2-negative (triple-negative, TNBC) or ER-, PR- weakly positive and/or HER2- equivocal status
Stage:
I, II, or III
Treatment Phase:  Patients must not have metastatic disease
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Sailendra Vasireddy
Locations Where Open:
Locations Where Open: Memphis, GTR
Formal Study Name:  Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Anatomic Site:
Breast
Histology:
Breast Carcinoma
Mutation:
HER2+
Stage:
IV, Recurrent Breast Carcinoma
Treatment Phase:  Must have metastatic breast cancer and initiating or continuing trastuzumab-based HER-2 targeted therapy without concurrent anthracyclines in first or second line setting
Trial Phase:
  III
Trial Type:
  Supportive Care
Principal Investigator:
  Sailendra Vasireddy, MD
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto, Oxford, NEA
Formal Study Name:  A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Anatomic Site:
Breast
Histology:
Any
Mutation:
Stage:
Any
Treatment Phase:  Patients must have inflammatory breast cancer without distant metastases
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, NEA
Formal Study Name:  Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Anatomic Site:
Colorectal Cancer
Histology:
Any
Mutation:
N/A
Stage:
IV
Treatment Phase:  Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Shailesh Satpute
Locations Where Open:
Locations Where Open: Memphis, DeSoto
Formal Study Name:  BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Anatomic Site:
Colorectal
Histology:
Any
Mutation:
N/A
Stage:
II or III
Treatment Phase:  Planning or undergone surgical resection of adenocarcinoma of the colon or rectum
Trial Phase:
  N/A
Trial Type:
  Supportive Care
Principal Investigator:
  Dr. Donald Gravenor
Locations Where Open:
Locations Where Open: Women’s
Formal Study Name:  Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Anatomic Site:
Breast
Histology:
Mutation:
Stage:
Treatment Phase:  Patients must not have previous personal history of breast cancer including ductal carcinoma in situ. Patients must be scheduled for, or have intent to schedule, a screening mammogram
Trial Phase:
  III
Trial Type:
  Screening/Interventional
Principal Investigator:
  Lynn Gayden, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto
Formal Study Name:  A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Anatomic Site:
Multiple Myeloma
Histology:
Any
Mutation:
Stage:
Any, but must be newly diagnosed
Treatment Phase:  Have newly diagnosed multiple myeloma with a history of 4 to 8 total cycles of induction with or without consolidation therapy and have received high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Donald Gravenor
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Anatomic Site:
Lung
Histology:
Non-small cell lung cancer
Mutation:
N/A
Stage:
I, II, or III
Treatment Phase:  Complete recovery from surgery. Registration to A081801 must be 30-77 days following surgery. Must be previously registered to A151216
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Edward Todd Robbins
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Anatomic Site:
Lung
Histology:
Advanced Nonsquamous Non-Small Cell Lung Cancer
Mutation:
PD-L1 expression Tumor Proportion Score (TPS) >= 1% in tumor cells
Stage:
IV; Patients with Stage IIIB and IIIC disease are eligible if they are not candidates for combined chemotherapy and radiation
Treatment Phase:  Patients must NOT have received the following: prior systemic chemotherapy or immunotherapy
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Memphis, DeSoto, NEA
Formal Study Name:  Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Anatomic Site:
Lung
Histology:
Non-small cell lung cancer
Mutation:
Any
Stage:
IIIA/B/C
Treatment Phase:  Newly diagnosed stage IIIA/B/C non-small cell lung cancer (NSCLC) (per the American Joint Committee on Cancer [AJCC] 8th edition) that is unresectable and is histologically and/or cytologically confirmed; Nodal recurrence after surgery for early stage NSCLC
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Memphis, DeSoto, NEA
Formal Study Name:  A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE
Anatomic Site:
Lung
Histology:
Advanced Non-Squamous Non-Small Cell Lung Cancer
Mutation:
Any
Stage:
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Treatment Phase:  Receipt of at least one but not more than two prior treatment regimens in the advanced setting; Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotherapy followed by checkpoint inhibitor therapy)
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers & Dr. Carroll Scroggin
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, NEA
Formal Study Name:  Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Anatomic Site:
Lung
Histology:
Limited Stage Small Cell Lung Cancer
Mutation:
Any
Stage:
Stage Tx, T1-T4, N0-3, M0
Treatment Phase:  Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer [AJCC] staging, 8th edition [Ed.]), within 60 days prior to registration
Trial Phase:
  II/III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Raymond Osarogiagbon
Locations Where Open:
Locations Where Open: Memphis, DeSoto
Formal Study Name:  MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Anatomic Site:
Lung
Histology:
Small Cell Lung Cancer
Mutation:
Any
Stage:
Extensive Stage or Limited Stage Small Cell Lung Cancer
Treatment Phase:  Any
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Shailesh Satpute
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Anatomic Site:
Lung
Histology:
Extensive Stage Small Cell Lung Cancer
Mutation:
SLFN11 Positive
Stage:
Extensive Stage Small Cell Lung Cancer
Treatment Phase:  Participants must have completed at least one cycle of frontline induction treatment with platinum plus etoposide plus atezolizumab prior to Step 1 Screening Registration. Cycle 1 of frontline induction treatment may or may not contain Atezolizumab
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Dr. Sailendra Vasireddy
Locations Where Open:
Locations Where Open: Memphis, DeSoto, NEA
Formal Study Name:  A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Anatomic Site:
Lung
Histology:
Non-small cell lung cancer
Mutation:
Any
Stage:
II or III
Treatment Phase:  Participants must not be candidates for surgical resection in the opinion of the treating investigator. Participants whose disease was previously resected must have experienced local or regional recurrence at least 12 months after resection
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Dr. Kathleen Spiers
Locations Where Open:
Locations Where Open: Memphis
Formal Study Name:  Procurement of Human Biospecimens for Current and Future Medical Research
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Cancer
Mutation:
Stage:
Any
Treatment Phase:  Has not had any previous treatment or has not had any treatment within the last 6 months
Trial Phase:
  
Trial Type:
  
Principal Investigator:
  Todd Robbins, MD
Study Link:  
Locations Where Open:
Locations Where Open: Memphis, DeSoto
Formal Study Name:  A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Anatomic Site:
Blood and Marrow
Histology:
Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Mutation:
Stage:
Treatment Phase:  Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. R-CHOP, DA-EPOCH-R, etc); No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies)
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Muhammad Raza, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto
Formal Study Name:  A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Anatomic Site:
Blood and Marrow
Histology:
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Mutation:
Stage:
Treatment Phase:  Referrals must be made as early as possible but no later than 5 calendar days after ATRA therapy is initiated; consent can be obtained up till day 7 or earlier
Trial Phase:
  
Trial Type:
  Prevention
Principal Investigator:
  Salil Goorha, MD
Locations Where Open:
Locations Where Open: Memphis
Formal Study Name:  A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Anatomic Site:
Blood and Marrow
Histology:
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Mutation:
Stage:
Treatment Phase:  Relapsed or refractory to prior standard therapy
Trial Phase:
  II/III
Trial Type:
  Treatment
Principal Investigator:
  Salil Goorha, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Collierville, Oxford, Grenada, New Albany, GTR, NEA
Formal Study Name:  NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Anatomic Site:
Any
Histology:
Any
Mutation:
Any
Stage:
Any
Treatment Phase:  Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy)
Trial Phase:
  
Trial Type:
  Cancer Control and Prevention
Principal Investigator:
  Dr. Raymond Osarogiagbon
Locations Where Open:
Locations Where Open: Memphis, Women’s, DeSoto, GTR, NEA
Formal Study Name:  A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Anatomic Site:
Breast
Histology:
HER2+
Mutation:
Stage:
III or IV
Treatment Phase:  Histologically confirmed adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Philip Lammers
Locations Where Open:
Locations Where Open: Jackson, Memphis, NEA
Formal Study Name:  A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Anatomic Site:
Ovarian, Fallopian Tube, or Primary Peritoneal
Histology:
Any
Mutation:
Stage:
II, III, or IV
Treatment Phase:  Patients must have newly diagnosed, stage II-IV low-grade serous ovarian cancer. Ovarian cancer = ovarian, fallopian tube and primary peritoneal cancers
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. David Engle
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, NEA
Formal Study Name:  A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Anatomic Site:
Pancreas
Histology:
Any
Mutation:
N/A
Stage:
Tx-4, N0-1, M0
Treatment Phase:  Any
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Stephen Behrman
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumor
Anatomic Site:
Any
Histology:
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal, Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional, Cell Carcinoma, Bladder Adenocarcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell, Carcinoma, Desmoid-Type Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastrointestinal Stromal Tumor, Giant Cell Carcinoma, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Carcinoid Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Testicular Sex Cord-Stromal Tumor, Metaplastic Breast Carcinoma Metastatic Malignant Neoplasm of Unknown Primary Origin, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Placental Choriocarcinoma, Placental-Site Gestational Trophoblastic Tumor, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma. Spindle Cell Neoplasm, Squamous Cell Carcinoma of the Penis, Teratoma With Malignant Transformation, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Undifferentiated Gastric Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma (Not Otherwise Specified), Vulvar Carcinoma
Mutation:
Stage:
Any
Treatment Phase:  Patients must have progressed following at least one line of standard systemic therapy or patients for whose disease no standard treatment exists that has been shown to prolong overall survival
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Donald Gravenor, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Anatomic Site:
Breast
Histology:
Hormone Receptor Positive, HER2 Negative
Mutation:
Stage:
Any
Treatment Phase:  Patients must have a diagnosis of hormone receptor positive (estrogen receptor positive [ER+] and/or progesterone receptor positive [PR+]), HER-2 negative, metastatic (M1) breast cancer and must be receiving or plan to receive first-line systemic treatment for metastatic disease
Trial Phase:
  
Trial Type:
  Treatment
Principal Investigator:
  Dr. Drew Dill
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, Grenada, New Albany
Formal Study Name:  A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Anatomic Site:
Chronic myeloid leukemia
Histology:
Without any history of progression to accelerated or blast phase CML
Mutation:
BCR-ABL1 Positive
Stage:
Any
Treatment Phase:  Patients must have a diagnosis of chronic phase chronic myeloid leukemia without any history of progression to accelerated or blast phase CML; no new bone marrow aspiration and biopsy is needed to prove diagnosis prior to randomization; however, documentation stating the patient is in chronic phase is required
Trial Phase:
  II
Trial Type:
  Treatment
Principal Investigator:
  Dr. Donald Gravenor
Locations Where Open:
Locations Where Open: Memphis, DeSoto, NEA
Formal Study Name:  A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Anatomic Site:
Any
Histology:
Hodgkin Lymphoma
Mutation:
Stage:
III or IV
Treatment Phase:  Histologically confirmed newly diagnosed, previously untreated stage III or IV classical Hodgkin lymphoma (nodular sclerosing, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS])
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Dr. Salil Goorha
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, NEA
Formal Study Name:  A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Anatomic Site:
GI
Histology:
Colon Cancer, Rectal Cancer
Mutation:
Stage:
Stage 0, I, II, or III
Treatment Phase:  Patients must have received primary resection 1 year previously and be at least 30 days from completion of adjuvant chemotherapy and radiation therapy.
Trial Phase:
  III
Trial Type:
  Prevention
Principal Investigator:
  Stephen Behrman, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST screening trial)
Anatomic Site:
Lung
Histology:
Squamous, Non-Small Cell Lung Cancer (NSCLC), Large Cell Lung Carcinoma
Mutation:
Stage:
Squamous & SCLC: Stage IB, Stage IIA, Stage IIB, Stage IIIA
Treatment Phase:  Patients with suspected diagnosis of resectable or completely resected NSCLC and have not received neoadjuvant therapy for this cancer.
Trial Phase:
  
Trial Type:
  Screening
Principal Investigator:
  Todd Robbins, MD
Locations Where Open:
Locations Where Open: Memphis, DeSoto, Oxford, New Albany, Grenada, GTR, NEA
Formal Study Name:  A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Anatomic Site:
Lung
Histology:
Non-Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Mutation:
Fusion
Stage:
Carcinoma: Stage IB, Stage IIA, Stage IIB; NSCLC: Stage IIIA
Treatment Phase:  Patients have undergone complete surgical resection of their cancer and have negative margins and registered to A151216.
Trial Phase:
  III
Trial Type:
  Treatment
Principal Investigator:
  Todd Robbins, MD
Locations Where Open: